ALPS Advisors’s Cymabay Therapeutics CBAY Stock Holding History

ALPS Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-75,374	Closed	-$1.78M	–	1086
2023 Q4	$1.78M	Buy	75,374 +2,913	+4%	+$51.9K	0.01%	352
2023 Q3	$1.08M	Buy	72,461 +783	+1%	+$10.4K	0.01%	422
2023 Q2	$785K	Buy	71,678 +9,298	+15%	+$86.6K	0.01%	537
2023 Q1	$544K	Buy	62,380 +4,874	+8%	+$39K	﹤0.01%	582
2022 Q4	$361K	Buy	+57,506	New	+$219K	﹤0.01%	724
2018 Q4	–	Sell	-104,500	Closed	-$1.16M	–	960
2018 Q3	$1.16M	Buy	104,500 +19,213	+23%	+$239K	0.01%	348
2018 Q2	$1.15M	Buy	+85,287	New	+$1.07M	0.01%	307

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ALPS Advisors's CBAY Position: Q1 2024 in Review

ALPS Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 75,374 shares — an estimated $1.78M sold.

ALPS Advisors first reported a position in CBAY in Q2 2018 and held it in 7 quarters. The position peaked at $1.78M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

ALPS Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
ALPS Advisors sold 75,374 Cymabay Therapeutics shares in Q1 2024, an estimated $1.78M.
ALPS Advisors first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 7 quarters.
ALPS Advisors's Cymabay Therapeutics position peaked at $1.78M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on ALPS Advisors's 13F filing for Q1 2024, filed 14 May 2024.